Back | Next |
home / stock / onct / onct message board
Subject | By | Source | When |
---|---|---|---|
Oncternal Therapeutics Provides Business Update. | TechandBio | investorshub | 08/17/2022 9:53:05 PM |
Imbruvica (ibrutinib) Pharmacyclics (AbbVie) and Janssen (Johnson & J | TechandBio | investorshub | 08/17/2022 1:26:36 PM |
Outperform rating. Analyst Oppenheimer Hartaj Singh has | TechandBio | investorshub | 08/16/2022 6:45:07 PM |
Added again this one looks ready to go. | TechandBio | investorshub | 08/16/2022 1:46:23 PM |
Oncternal Therapeutics Drives Complete Responders with First in | TechandBio | investorshub | 08/16/2022 11:38:58 AM |
slapped the ask here a little. Let's go, | TechandBio | investorshub | 08/15/2022 3:23:16 PM |
VIDEO ZILO-301: Phase III study of zilovertamab + | TechandBio | investorshub | 08/13/2022 5:10:52 PM |
10x-20x Potential in the cards DD | TechandBio | investorshub | 08/13/2022 1:44:54 AM |
Took a starter here. | TechandBio | investorshub | 08/13/2022 1:35:07 AM |
H.C. Wainwright Thinks Oncternal Therapeutics Stock is Going | Golden Cross | investorshub | 05/31/2022 11:36:16 AM |
It moved finally I expect more to come | robertus | investorshub | 05/29/2022 7:53:46 PM |
znewcar1: ONCT 88% v20,7M c1.54 f49,4M H1.61 BO1.1 and pushed to hod | znewcar1 | investorshangout | 05/27/2022 8:09:46 PM |
Good to go now | Triple nickle | investorshub | 05/27/2022 2:11:47 PM |
Im on it | Triple nickle | investorshub | 05/27/2022 1:46:27 PM |
znewcar1: ONCT 23% v963K c1.05 f49,4M H1.07 YL.85 | znewcar1 | investorshangout | 05/03/2022 1:36:28 AM |
https://www.benzinga.com/wiim/22/01/24894238/oncternal-therapeutics-shares- | zetatauri | investorshub | 01/05/2022 12:51:39 PM |
https://seekingalpha.com/article/4447087-oncternal-therapeutics-inc-onct-ce | zetatauri | investorshub | 08/09/2021 1:10:32 PM |
Of course. My question was from last November. | KingOfSwing...Trading | investorshub | 07/21/2021 10:50:24 PM |
Very much so. I saw your post | zetatauri | investorshub | 07/21/2021 10:40:02 PM |
ONCT board inactive | 4gh1rx | investorshub | 07/21/2021 9:36:46 PM |
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NYSE Market:
Oncternal Therapeutics Inc. Website:
2024-06-26 15:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the fifth dose cohort of its Phas...
Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the ...